K-ras mutations and benign pancreatic disease

International Journal of Pancreatology

Volumn 27, Issue 2, 2000, Pages 93-103

  Löhr, Matthias ^a   Maisonneuve, Patrick ^b   Lowenfels, Albert B ^c  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Chronic pancreatitis; Endoscopy; K ras; Molecular diagnosis; Pancreatic carcinoma; PCR; Pure pancreatic juice; Ras mutation

Indexed keywords

CYCLIN D; MITOGEN ACTIVATED PROTEIN KINASE; RAS PROTEIN;

AGED; CANCER INCIDENCE; CASE REPORT; DNA DETERMINATION; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; ONCOGENE K RAS; PANCREAS DISEASE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

EID: 0034121655     PISSN: 01694197     EISSN: None     Source Type: Journal    
DOI: 10.1385/ijgc:27:2:093     Document Type: Review

References (123)

1. 1 Bishop JM. Cellurar oncogenes and retroviruses. Annu Rev Biochem 1983; 52: 301-354.
2. 2 Weinberg RA. Growth factors and oncogenes, in Oncogenes and the Molecular Origins of Cancer, Weinberg RA, ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY 1989; pp. 45-66.
3. 3 McCormick F. ras Oncogenes, in Oncogenes and the Molecular Origins of Cancer, Weinberg RA, ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY 1989; pp. 125-145.
4. 4 Harvey JJ. An unidentified virus which causes the rapid production of tumors in mice. Nature 1964; 204: 1104, 1105.
5. 5 Kirsten WH, Mayer LA. Morphologic responses to a murine erythroblastosis virus. J Natl Cancer Inst 1967; 39: 311-335.
6. 6 Ellis RW, DeFeo D, Shih TY, Gonda MA, Young HA, Tsuchida N, et al. The p21 src genes of Harvey and Kirsten sarcoma virus originate from divergent members of a family of normal vertebrate genes. Nature 1981; 292: 506-511.
7. 7 Bos JL. p21 ras: an oncoprotein functioning in growth factor-induced signal transduction. Eur J Cancer 1995; 31A: 1051-1054.
8. 8 Garrington TP, Johnson GL. Organization and regulation of mitogen-activated protein kinase signaling pathways. Curr Opin Cell Biol 1999; 11: 211-218.
9. 9 Malumbres M, Pellicer A. Ras pathways to cell cycle control and cell transformation. Frontiers Biosci 1998; 3: e887-e912
10. 10 Rozenblum E, Schutte M, Goggins M, Hahn SA, Panzer S, Zahurak M, et al. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 1997; 57: 1731-1734.
11. 11 Schutte M, Kern SE. The molecular genetics of pancreatic adenocarcinoma, in Pancreatic cancer. Molecular and clinical advances, Neoptolemos JP, Lemoine NR, eds. Blackwell Science, Oxford. 1996: pp. 115-132.
12. 12 Ruggeri B, Zhang S-Y, Caamano J, DiRado M, Flynn SD, Klein-Szanto AJP. Human pancreatic carcinomas and cell lines reveal frequent and multiple alterations in the p53 and Rb-1 tumor suppressor genes. Oncogene 1992; 7: 1503-1511.
13. 13 Hahn SA, Schutte M, Hoque ATMS, Moskaluk CA, da Costa LT, Rozenblum E, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996; 271: 350-353.
14. 14 Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759, 760.
15. 15 Hall PA, Lemoine NR. Models for pancreatic cancer, Cancer Surveys, vol. 16: The Molecular Pathology of Cancer, in Lemoine NR, Wright NA, eds. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY 1993: pp. 135-155.
16. 16 Terhune PC, Phifer DM, Tosteson TD, Longnecker DS. K-ras mutation in focal proliferative lesions of human pancreas. Cancer Epidemiol Biomark Prevent 1998; 7: 515-521.
17. 17 Lüttges J, Reinecke-Lüthge A, Möllmann B, Menke MAOH, Clemens A, Klimpfinger M, et al. Duct changes and k-ras mutations in the disease-free pancreas: analysis of type, age relation and spatial distribution. Virch Arch 1999; 435: 37-45.
18. 18 Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA. Creation of human tumour cells with defined genetic elements. Nature 1999; 400: 464-468.
19. 19 Parkin DM, Pisari P, Ferlay J. Estimates of the world incidence of 25 major cancers in 1990. Intl J Cancer 1999; 80: 827-841.
20. 20 Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics 1996. CA Cancer J Clin 1996; 46: 5-27.
21. 21 Lowenfels AB, Maisonneuve P, Cavallini G, Ammann RW, Lankisch PG, Andersen JR, et al. Pancreatitis and the risk of pancreatic cancer. N Engl J Med 1993; 328: 1433-1437.
22. 22 Ammann RW. Zur Klinik und Differentialdiagnose der chronischen Pankreatitis. Dtsch Med Wchnschr 1980; 110: 1322-1327.
23. 23 Löhr M, Holle A, Liebe S. Differentiating chronic pancreatitis from pancreatic carcinoma, in Chronic pancreatitis, Izbicki JR, Bienmoeller KF, Soehendra N, eds. De Gruyter, Berlin 1997; pp. 45-58.
24. 24 Evans JD, Morton DC, Neoptolemos JP. Chronic pancreatitis and pancreatic carcinoma. Postgrad Med J 1997; 73: 543-548.
25. 25 Grünewald K, Lyons J, Fröhlich A, Feichtinger H, Weger RA, Schwab G, et al. High frequency of ki-ras codon 12 mutations in pancreatic adenocarcinomas. Intl J Cancer 1989; 43: 1037-1041.
26. 26 Scarpa A, Capelli P, Villanueva A, Zamboni G, Lluís F, Accolla R, et al. Pancreatic cancer in Europe: ki-ras mutation pattern shows geographical differences. Intl J Cancer 1994; 57: 167-171.
27. 27 Capellá G, Cronauer-Mitra S, Peinado MA, Perucho M. Frequency and spectrum of mutations at codon 12 and 13 of the c-k-ras gene in human tumors. Environ Health Perspect 1991; 93: 125-131.
28. 28 Daus H, Trümper L, Bürger B, Jacobs G, Kriener S, von Blohn G, et al. Ki-ras-Mutation als molekularer Tumor-marker für Pankreaskarzinome. Dtsch Med Wchnschr 1995; 120: 821-826.
29. 29 Heller T, Trautmann B, Zöller-Utz I, König HJ, Ell C, Liebe S, et al. Restriktionsenzym-Mismatch-Polymerase-Kettenreaktion zum Nachweis von ki-ras-Onkogen-Mutationen beim Pankreaskarzinom. Dtsch Med Wchnschr 1995; 120: 826-830.
30. 30 Brentnall TA, Chen R, Lee JG, Kimmey MB, Bronner MP, Haggitt RC, et al. Microsattelite instability and k-ras mutations associated with pancreatic adenocarcinoma and pancreatitis. Cancer Res 1995; 55: 4264-4267.
31. 31 Villanueva A, Reyes G, Cuatrecasas M, Martínez A, Erill N, Lerma E, et al. Diagnostic utility of k-ras mutations in fine-needle aspirates of pancreatic masses. Gastroenterology 1996; 110: 1587-1594.
32. 32 Mullis KB, Faloona FA. Specific synthesis of DNA in vitro via a polymerase cutalyzed chain reaction. Methods Enzymol 1987; 155: 335-350.
33. 33 Scarpa A, Capelli P, Villanueva A, Zamboni G, Lluís F, Accolla R, et al. Pancreatic cancer in Europe: ki-ras mutation pattern shows geographical differences. Intl J Cancer 1994; 57: 167-171.
34. 34 Motojima K, Urano T, Nagata Y, Shiku H, Tsurifune T, Kanematsu T. Detection of point mutations in the kirstenras oncogene provides evidence of the multicentricity of pancreatic carcinoma. Ann Surg 1993; 217: 138-143.
35. 35 Reyes G, Villanueva A, Garciá C, Sancho FJ, Piulats J, Lluís F, et al. Orthotopic xenografts of human pancreatic carcinomas acquire genetic aberrations during dissemination in nude mice. Cancer Res 1996; 56: 5713-5719.
36. 36 Rivera JA, Fernandez-del Castillo C, Rall CJN, Graeme-Cook F, Warshaw AL, Rustgi AK. Analysis of k-ras mutations in chronic pancreatitis with ductal hyperplasia. Gastroenterology 1995; /1695 Abstract.
37. 37 Lüttges J, Schlehe B, Menke MAOH, Vogel I, Henne-Bruns D, Klöppel G. The k-ras mutation pattern in pancreatic ductal adenocarcinoma is usually identical to that in associated normal, hyperplastic and metaplastic duct epithelium. Cancer 1999; 85: 1703-1710.
38. 38. Brat DJ, Lillemoe KD, Yeo CJ, Warfield PB, Hruban RH. Progression of pancreatic intraductal neoplasias to infiltrating adenocarcinoma of the pancreas. Am J Surg Pathol 1998; 22: 163-169.
39. 39 Sugio K, Gadzar AF, Albores-Saavedra J, Kokkinakis DM. High yields of k-ras mutations in intraductal papillary mucinous tumors and invasive adenocarcinomas induced by N-nitroso(2-hydroxypropyl)(2-oxopropyl)amine in the pancreas of female Syrian hamsters. Carcinogenesis 1996; 17: 303-309.
40. 40 Obara T, Saitoh Y, Maguchi H, Ura H, Kitazawa S, Koike Y, et al. Multicentric development of pancreatic intraductal carcinoma through atypical papillary hyperplasia. Hum Pathol 1992; 23: 82-85.
41. 41 Tsutsumi M, Kondoh S, Noguchi O, Horiguchi K. Kobayashi E, Okita S, et al. K-ras gene mutation in early ductal lesions induced in a rapid production model for pancreatic carcinomas in Syrian hamsters. Jpn J Cancer Res 1993; 84: 1101-1105.
42. 42 Cylwik B, Nowak HF, Puchalski Z, Barczyk J. Epithelial anomalies in chronic pancreatitis as a risk factor of pancreatic cancer. Hepato-Gastroenterol 1998; 45: 528-532.
43. 43 Tenner S, Carr-Locke DL, Banks P, Brooks DC, Van Dam J, Farraye FA, et al. Intraductal mucin-hypersecreting neoplasm "mucinous ductal ectasia": endoscopic recognition and management. Am J Gastroenterol 1996; 91: 2548-2554.
44. 44 Miki H, Matsumoto S, Harada H, Mori S, Haba R, Ochi K, et al. Detection of c-ki-ras point mutation from pancreatic juice. Intl J Pancreatol 1993; 14: 145-148.
45. 45 Kondo H, Sugano K, Fukayama N, Kyogoku A, Nose H, Shimada K, et al. Detection of point mutations in the k-ras oncogene at codon 12 in pure pancreatic juice for diagnosis of pancreatic carcinoma. Cancer 1994; 73: 1589-1594.
46. 46 Müller P, Jesnowski R, Liebe S, Rolfs A, Löhr M. Simple method for DNA extraction from pancreatic juice for PCR amplification assays. Intl J Pancreatol 1999; 25: 39-43.
47. 47 Orth M, Ludwig L, Glasbrenner B, Preclik G, Adler G, Schmid RM. Einflußder Probenaufbereitung für den Nachweis von ki-ras-Mutationen aus Galle und Pankreassekret. Z Gastroenterol 1997; 35: 765/A148 Abstract.
48. 48 Anker P, Lefort F, Vasioukin V, Lyautey J, Lederrey C, Chen XQ, et al. K-ras mutations are found in DNA extracted from the plasma of patients with colorectal cancer. Gastroenterology 1997; 112: 1114-1120.
49. 49 Tada M, Omata M, Kawai S, Saisho H, Ohto M, Saiki RK, et al. Detection of ras gene mutation in pancreatic juice and peripheral blood of patients with pancreatic adenocarcinoma. Cancer Res 1993; 53: 2472-2474.
50. 50 Mulcahy HE, Lyautey J, Lederrey C, Chen X, Anker P, Alstead EM, et al. A prospective study of k-ras mutations in the plasma of pancreatic cancer patients. Clin Cancer Res 1998; 4: 271-275.
51. 51 Caldas C, Hahn SA, Hruban RH, Redston MS, Yeo CJ, Kern SE. Detection of k-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res 1994; 54: 3568-3573.
52. 52 Lowenfels AB, Maisonneuve P, Cavallini G, Ammann RW, Lankisch PG, Andersen JR, et al. Pancreatitis and the risk of pancreatic cancer. N Engl J Med 1993; 328: 1433-1437.
53. 53 Uehara H, Nakaizumi A, Baba M, Iishi H, Tatsuta M, Kitamura T, et al. Diagnosis of pancreatic cancer by k-ras point mutation and cytology of pancreatic juice. Am J Gastroenterol 1996; 91: 1616-1621.
54. 54 Löhr M, Müller P, Mora J, Brinkmann B, Ostwald C, Plath F, et al. Multiple genetic alterations in pancreatic juice samples in patients with chronic pancreatitis suggests smoking as a contributing factor for ras mutations. Submitted 1999.
55. 55 Müller J, Gansauge S, Schmid R, Gansauge F, Adler G, Beger HG. p53, nicht aber k-ras Mutationen können bei chronischer Pankreatitis gefunden werden. Langenbecks Arch Chir 1997; 114 (Suppl Kongress): 715-718.
56. 56 Watanabe H, Sawabu N, Ohta H, Satomura Y, Yamakawa O, Motoo Y, et al. Identification of k-ras oncogene mutations in the pure pancreatic juice of patients with ductal pancreatic cancers. Jpn J Cancer Res 1993; 84: 961-965.
57. 57 van Laethem JL, Vertongen P, Deviere J, van Rampelbergh J, Rickaert F, Cremer M, et al. Detection of c-ki-ras gene codon 12 mutations from pancreatic duct brushings in the diagnosis of pancreas tumors. Gut 1995; 36: 781-787.
58. 58 Hsiang D, Friess H, Büchler MW, Ebert M, Butler J, Korc M. Absence of k-ras mutations in the pancreatic parenchyma of patients with chronic pancreatitis. Am J Surg 1997; 174: 242-246.
59. 59 Gansauge S, Schmid RM, Müller J, Adler G, Mattfeldt T, Beger HG. Genetic alterations in chronic pancreatitis: evidence for early occurence of p53 but not k-ras mutations. Br J Surg 1998; 85: 337-340.
60. 60 Steinberg WM, Barkin J, Bradley EL, DiMagno E, Layer P, Brentnall T, et al. Controversies in clinical pancreatology. Workup of a patient with familiar pancreatic cancer. Pancreas 1999; 18: 219-224.
61. 61 Furuya N, Kawa S, Akamatsu T, Furihata K. Long-term follow-up of patients with chronic pancreatitis and k-ras gene mutation detected in pancreatic juice. Gastroenterology 1997; 113: 593-598.
62. 62 Talamini G, Falconi M, Bassi C, Sartori N, Salvia R, Caldiron E, et al. Incidence of cancer in the course of chronic pancreatitis. Am J Gastroenterol 1999; 94: 1253-1260.
63. 63 Berthélemy P, Bouisson M, Escourrou J, Vayesse N, Rumeau JL, Pradayrol L. Identification of K-ras mutations in pancreatic juice in the early diagnosis of pancreatic cancer. Ann Intern Med 1995; 123: 188-191.
64. 64 Ochi K, Hasuoka H, Mizushima T, Matsumura N, Harada H. A case of small pancreatic cancer diagnosed by serial follow-up studies promptly by a positive K-ras point mutation in pure pancreatic juice. Am J Gastroenterol 1998; 93: 1366-1368.
65. 65 Wakabayashi T, Sawabu N, Watanabe H, Morimoto H, Sugioka G, Takita Y. Detection of K-ras point mutation at codon 12 in pure pancreatic juice collected 3 years and 6 months before the clinical diagnosis of pancreatic cancer. Am J Gastroenterol 1996; 91: 1848-1851.
66. 66 Suehara N, Mizumoto K, Kusumoto M, Niiyama H, Ogawa T, Yamaguchi K, et al.Telomerase activity detected in pancreatic juice 19 months before a tumor is detected in a patient with pancreatic cancer. Am J Gastroenterol 1998; 93: 1967-1971.
67. 67 Klingelhutz AJ. Telomerase activation and cancer. J Mol Med 1997; 75: 45-49.
68. 68 Behn M, Qun S, Pankow W, Havemann K, Schuermann M. Frequent detection of ras and p53 mutations in brush cytology samples from lung cancer patients by a restriction fragment length polymorphism-based enriched PCR technique. Clin Cancer Res 1998; 4: 361-371.
69. 69 Keohavong P, Zhu D, Whiteside TL, Swalsky P, Bakker A, Elder EM, et al. Detection of infrequent and multiple K-ras mutations in human tumors and tumor-adjacent tissues. Anal Biochem 1997; 247: 394-403.
70. 70 Rolfs A, Schuller I, Finckh U, Weber-Rolfs I. PCR. Clinical Diagnostics and Research. Springer, Heidelberg, 1993.
71. 71 Tada M, Teratani T, Komatsu Y, Kawabe T, Shiratori Y, Omata M. Quantitative analysis of ras gene mutation in pancreatic juice for diagnosis of pancreatic adenocarcinoma. Dig Dis Sci 1998; 43: 15-20.
72. 72 Barnard R, Futo V, Pecheniuk N, Slattery M, Walsh T. PCR bias toward the wild-type k-ras and p53 sequences: implications for PCR detection of mutations and cancer diagnosis. Biotechniques 1998; 25: 684-691.
73. 73 Nakaizumi A, Uehara H, Takenaka A, Uedo N, Sakai N, Yano H, et al. Diagnosis of pancreatic cancer by cytology and measurement of oncogene and tumor markers in pure pancreatic juice aspirated by endoscopy. Hepatogastroenterology 1999; 46: 31-37.
74. 74 Orti E, Canelles P, Tome A, Calvo MAMM, Medina E, Benages A. Diagnostic value of aspiration cytology with ERCP. Rev Esp Enferm Dig 1993; 84: 173-177.
75. 75 Del Favero G, Fabris C, Angonese C, Basso D, Rebuffi A, Costantin G, et al. Cytology in the diagnosis of pancreatic cancer. Intl J Pancreatol 1988; 3 (Suppl. 1): S137-S141.
76. 76 Gordis L, Gold EB. Epidemiology and etiology of pancreatic cancer, in The Pancreas. Biology, Pathobiology and Disease. Go VLW, DiMagno EP, Gardner JD, Lebenthal E, Reber HA, Scheele GA, eds. 2nd ed., Raven Press, New York 1993: pp. 837-855.
77. 77 Auerbach O, Garfinkel L. Histologic changes in pancreas in relation to smoking and coffee-drinking habits. Digest Dis Sci 1986; 31: 1014-1020.
78. 78 Weiderpass E, Partanen T, Kaaks R, Vainio H, Porta M, Kauppinen T, et al. Occurence, trends and enviromental etiology of pancreatic cancer. Scand J Work Environ Health 1998; 24: 165-174.
79. 79 Chang KW, Laconi S, Mangold KA, Hubchak S, Scarpelli DG. Multiple genetic alterations in hamster pancreatic duetal adenocarcinomas. Cancer Res 1995; 55: 2560-2568.
80. 80 Carbone D. Smoking and cancer. Am J Med 1992; 93 (Suppl 1A): 1A-13S-1A-17S.
81. 81 Berger DH, Chang H, Wood M, Huang L, Heath CW, Lehman T, et al. Mutational activation of k-ras in nonneoplastic exocrine pancreatic lesions in relation to cigarette smoking status. Cancer 1999; 85: 326-332.
82. 82 Gold EB. Epidemiology of and risk factor for pancreatic cancer. Surg Clin North Am 1995; 75: 819-845.
83. 83 Porta M, Malats N, Guarner L, Carrato A, Rifá J, Salas A, et al. Association between coffee drinking and K-ras mutations in exocrine pancreatic cancer. J Epidemiol Community Health 1999; 53: 702-709.
84. 84 Vineis P. ras mutations and a cup of coffee: cause, confounder, effect, modifier, or what else? J Epidemiol Community Health 1999; 53: 685
85. 85 Whitcomb DC, Gorry MC, Preston RA, Furey W, Sossenheimer MJ, Ulrich CD, et al. Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. Nature Genet 1996; 14: 141-145.
86. 86 Keim V, Teich N, Reich A, Mössner J. Trypsinogen mutations of exons 2 and 3 in hereditary and chronic-alcoholic pancreatitis. Gastroenterology 1998; 114: A473/G1925 Abstract.
87. 87 Orth M, Gansauge F, Gansauge S, Beger HG, Adler G, Schmid RM. K-ras mutations at codon 12 are rare events in chronic pancreatitis. Digestion 1998; 59: 120-124.
88. 88 Müller P, Heller T, Stelt HJ, Emmrich J, Zingler C, Nizze H, et al. Welche Bedeutung haben ras-und p53-Mutationen im Pankreassekret bei Patienten mit chronischer Pankreatitis? Z Gastroenterol 1996; 34: 554/V5 Abstract.
89. 89 Longnecker DS, Terhune PG. What is the true rate of k-ras mutation in carcinoma of the pancreas? Pancreas 1998; 17: 323-324.
90. 90 Herzig KH, Schaffer M, Rosewicz S, Fölsch UR. Detection of mutated ras-oncogene in pancreatic cancers: improved diagnostoc possibilities using molecular biology techniques? Z Gastroenterol 1992; 30: 436-439.
91. 91 Urrutia R, DiMagno EP. Genetic markers: the key to early diagnosis and improved survival in pancreatic cancer? (editorial). Gastroenterology 1996; 110: 306-310.
92. 92 Schmid RM, Adler G. Ki-ras-Mutationen - ein spezifischer und sensitiver Tumormarker für das Pankreaskarzinom? Dtsch Med Wchnschr 1995; 120: 830-833.
93. 93 Chu TM. Molecular diagnosis of pancreas carcinoma. J Clin Lab Anal 1997; 11: 225-231.
94. 94 Satoh K, Shimosegawa T, Moriizumi S, Koizumi M, Toyota T. K-ras mutation and p53 protein accumulation in intraductal mucin-hypersecreting neoplasms of the pancreas. Pancreas 1996; 12: 362-368.
95. 95 Pasrichu PJ. ERCP meets c-k-ras: towards an improved diagnosis of pancreatic cancer. Gastroenterology 1996; 110: 311-317.
96. 96 Hahn SA, Kern SE, Schmiegel WH. Neue molekularbiologische Erkenntnisse aus der Pankreaskarzinomforschung. Dtsch Ärztebl 1997; 94: 3342-3350.
97. 97 Hall PA, Lemoine NR. Koch's postulates revisited. J Pathol 1991; 164: 283,284.
98. 98 Hall PA, Lemoine NR. Models for pancreatic cancer in Cancer Surveys, vol. 16: The Molecular Pathology of Cancer, Lemoine NR, Wright NA, eds. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY 1993: pp. 135-155.
99. 99 Jesnowski R, Liebe S, Löhr M. Increasing the transfection efficacy and subsequent long-term culture of resting human pancreatic duct epithelial cells. Pancreas 1998; 17: 262-265.
100. 100 Löhr M, Zauner I, Trautmann B, Thévenod F, Capellá G, Lluís F, et al. SV40-immortalized bovine pancreatic duct epithelial cells retain morphological and functional characteristics of their native counterpart. Submitted.
101. 101 Weitzman JB, Yaniv M. Rebuilding the road to cancer. Nature 1999; 400: 401,402.
102. 102 Ibrahim MS, Lofts RS, Jahrling PB, Henchal EA, Weedn VW, Northrup MA, et al. Real-time microchip PCR for detecting single-base differences in viral and human DNA. Anal Chem 1998; 70: 2013-2017.
103. 103 Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res 1996; 6: 986-994.
104. 104 Wittwer CT, Ririe KM, Andrew RV, David DA, Gundry RA, Balis UJ.The LightCycler: a microvolume multisample fluorimeter with rapid temperature control. Biotechniques 1997; 22: 176-181.
105. 105 Weiler J, Hoheisel JD. Combining the preparation of oligonucleotide arrays and synthesis of high-quality primers. Anal Biochem 1996; 243: 218-227.
106. 106 Wallace RW. DNA on a chip: serving up the genome for diagnostics and research. Mol Med Today 1997; 3: 384-389.
107. 107 Whitcombe D, Newton CR, Little S. Advances in approaches to DNA-based diagnostics. Curr Opin Biotechnol 1998; 9: 602-608.
108. 108 Tada M, Omata M, Ohto M. Clinical application of ras gene mutation for diagnosis of pancreatic adenocarcinoma. Gastroenterology 1991; 100: 233-238.
109. 109 Tabata T, Fujimori T, Maeda S, Yamamoto M, Saitoh Y. The role of ras mutation in pancreatic cancer, precancerous lesions, and chronic pancreatitis. Intl J Pancreatol 1993; 14: 237-244.
110. 110 Urban T, RICCI S, Grange JD, Lacave R, Boudghene F, Breittmayer F, et al. Detection of c-ki-ras mutation by PCR/RFLP analysis and diagnosis of pancreatic adenocarcinomas. J Natl Cancer Inst 1993; 85: 2008-2012.
111. 111 Trumper LH, Bürger B, von Bonin F, Hintze A, von Blohn G, Pfreundschuh M, et al. Diagnosis of pancreatic adenocarcinoma by polymerase chain reaction from pancreatic secretions. Br J Cancer 1994; 70: 278-284.
112. 112 Anton RC, Genta RM, Rajagopalan S. K-ras oncogene codon 12 mutation is an early event in the genesis of pancreatic adenocarcinoma. Proc Am Ass Cancer Res 1996; 37: Abstract.
113. 113 Iguchi H, Sugano K, Fukayama N, Ohkura H, Sadamoto K, Ohkoshi K, et al. Analysis of ki-rascodon 12 mutations in the duodenal juice of patients with pancreatic cancer. Gastroenterology 1996; 110: 221-226.
114. 114 Tada M, Ohashi M, Shiratori Y, Okudaira T, Komatsu Y, Kawabe T, et al. Analysis of k-ras gene mutation in hyperplastic duct cells of the pancreas without pancreatic disease. Gastroenterology 1996; 110: 227-231.
115. 115 Watanabe H, Sawabu N, Songur Y, Yamaguchi Y, Yamakawa O, Satomura Y, et al. Detection of K-ras point mutations at codon 12 in pure pancreatic juice for the diagnosis of pancreatic cancer by PCR/RFLP analysis. Pancreas 1996; 12: 18-24.
116. 116 Kondo H, Sugano K, Fukayama N, Hosokawa K, Ohkura H, Ohtsu A, et al. Detection of K-ras gene mutations at codon 12 in the pancreatic juice of patients with intraductal papillary mucinous tumors of the pancreas. Cancer 1997; 79: 900-905.
117. 117 Kondoh S, Kaino M, Okita S, Ryozawa S, Akiyama T, Okita K. Detection of ki-ras and p53 gene mutations in tissue and pancreatic juice from pancreatic adenocarcinomas. J Gastroenterol 1998; 33: 390-396.
118. 118 Watanabe H, Tamaguchi Y, Ha A, Hu YX, Motoo Y, Okai T, et al. Quantitative determination of K-ras mutations in pancreatic juice for diagnosis of pancreatic cancer using hybridization protection assay. Pancreas 1998; 17: 341-347.
119. 119 Nakaizumi A, Uehara H, Sugano S, Okada M, Tatsuta T, Kitamra H, et al. Small pancreatic cysts are the high risk for pancreatic cancer? -Analysis of k-ras gene mutation in the pancreatic juice. Gastroenterology 1997; 112 (Suppl.): A624 Abstract.
120. 120 Berndt C, Hauboldt K, Wenger F, Brux B, Müller J, Bendzko P, et al. K-ras mutations in stools and tissue samples from patients with malignant and nonmalignant pancreatic diseases. Clin Chem 1998; 44: 2103-2107.
121. 121 Zhang J, Tan CK, McMullen B, Downey KM, So AG. Cloning of the cDNAs for the small subunits of bovine and human DNA polymerase delta and chromosomal location of the human gene (POLD2)k. Genomics 1997; 29: 179-186.
122. 122 Wilentz RE, Chung CH, Sturm PDJ, Musler A, Sohn TA, Offerhaus GJA, et al. K-ras mutations in the duodenal fluid of patients with pancreatic carcinoma. Cancer 1998; 82: 96-103.
123. 123 Nakamura Y, Onda M, Uchida E. Analysis of k-ras codon 12 point mutations using duodenal lavage fluid for diagnosis of pancreatic carcinoma. Pancreas 1999; 18: 133-140.